Home > Newsletters > FDAnews Drug Daily Bulletin > Pfizer’s Zithromax to Undergo FDA Review for Increased Death Risk
FDAnews Drug Daily Bulletin
May 31, 2012 | Vol. 9 No. 107
Pfizer’s Zithromax to Undergo FDA Review for Increased Death Risk
The FDA is reviewing a study that found patients treated with Pfizer’s antibiotic Zithromax may be at a slightly higher risk for cardiovascular death than those taking amoxicillin, Bayer Healthcare’s Cipro or no drug. The risk of death from Zithromax (azithromycin) was small but was most pronounced in patients at a higher risk for cardiovascular disease, according to a study published in the May 17 issue of the New England Journal of Medicine.
Washington Drug Letter
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.